Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.

doi:10.1186/s13073-021-00926-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.

Genome medicine - 16 Jul 2021

Vangala Deepak, Ladigan Swetlana, Liffers Sven T, Noseir Soha, Maghnouj Abdelouahid, Götze Tina-Maria, Verdoodt Berlinda, Klein-Scory Susanne, Godfrey Laura, Zowada Martina K, Huerta Mario, Edelstein Daniel L, de Villarreal Jaime Martinez, Marqués Miriam, Kumbrink Jörg, Jung Andreas, Schiergens Tobias, Werner Jens, Heinemann Volker, Stintzing Sebastian, Lindoerfer Doris, Mansmann Ulrich, Pohl Michael, Teschendorf Christian, Bernhardt Christiane, Wolters Heiner, Stern Josef, Usta Selami, Viebahn Richard, Admard Jacob, Casadei Nicolas, Fröhling Stefan, Ball Claudia R, Siveke Jens T, Glimm Hanno, Tannapfel Andrea, Schmiegel Wolff, Hahn Stephan A

Abstract excerpt

BACKGROUND: The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested in vivo selection of anti-EGFR SR tumors in CRC patient-derived xenograft (PDX) models as a strategy for a molecular dissection of SR mechanisms. METHODS: We analyzed 21 KRAS, NRAS,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cellular Reprogramming

Share to Clonal Evolution

Share to DNA Copy Number Variations

Share to Drug Resistance, Neoplasm

Share to Exome Sequencing

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34271981
DOI: 10.1186/s13073-021-00926-7
PMCID: PMC8283888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.PMID 34271981Read ↗

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.Semantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Semantic proximity Read ↗

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts.Semantic proximity Read ↗

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just geneticsSemantic proximity Read ↗

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.Semantic proximity Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity Read ↗

Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.Semantic proximity Read ↗

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerSemantic proximity Read ↗

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell linesSemantic proximity Read ↗

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.